Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Mantle cell lymphoma (MCL) is not curable with conventional therapy. This study sought to
improve upon standard of care in newly diagnosed, untreated MCL patients who were
transplant-eligible using drugs already established as active in MCL. The combination of
Rituximab-Bendamustine followed by Rituximab-Cytarabine (RB/RC) was expected to maximize
pre-ASCT complete response (CR) rate compared to historical rates approximating 55% with
tolerable toxicity.